Ideaya's Darovasertib NDA Submission Complete; WAIT Stance Maintained Amid Rich Valuation
Read source articleWhat happened
Ideaya Biosciences has completed the NDA submission for darovasertib in HLA-A*02:01-negative metastatic uveal melanoma, as highlighted in a Seeking Alpha article maintaining a Strong Buy. The company is also planning registrational studies for IDE849 in GEP-NEC, with an FDA-aligned single-arm cohort that could support accelerated approval. Despite these milestones, the fundamental picture remains unchanged from the DeepValue master report: a pre-commercial biotech with ~$1.1B cash, no approved products, and a ~$3B market cap, trading at a premium to tangible assets. The stock has rallied 24% over the past year, but the valuation is still dominated by binary late-stage readouts and partner exits from GSK and Amgen. The NDA completion is a step forward but does not resolve the key efficacy and safety uncertainties that underpin the WAIT rating.
Implication
Investors should recognize that the NDA submission is a necessary but not sufficient condition for approval; the agency's review and potential AdCom will still scrutinize the totality of data, including overall survival and eye-preservation endpoints. IDE849's single-arm accelerated approval path adds optionality, but confirmation via randomized trials will be required, and competitive dynamics in DLL3-targeted therapies are intensifying. The cash runway into ~2030 provides downside cushion, yet the company's heavy R&D spend and history of partner attrition warrant continued caution. With the stock trading at several times tangible cash and no product revenue, the margin of safety remains thin. A more attractive entry point or clearer evidence of clinical differentiation across darovasertib and synthetic lethality assets is warranted before upgrading from WAIT.
Thesis delta
The prior WAIT stance is reiterated, but the completion of the darovasertib NDA submission reduces one regulatory milestone risk and could pull forward potential approval. IDE849's registrational strategy adds a second late-stage asset, but this does not mitigate the binary nature of upcoming efficacy data or the rich valuation. We maintain WAIT until pivotal readouts provide evidence of durable benefit and the market offers a better risk/reward.
Confidence
Moderate